Sign in

Tong Wang

@twangmdphd.bsky.social
170 followers 194 following 8 posts

physician-scientist in the Greenleaf Lab interested in chemical biology, epigenetics, and clinically useful tests.

PostsRepliesMedia
Reposted by Tong Wang
Abby Thurm @abbythurm.bsky.social · 30/06/2026
Great experience compiling years of collective screening experience to produce what we hope is a comprehensive protocol for others to accessibly scale up experiments! And some fun new data hidden in there :) @joshtycko.com www.nature.com/articles/s41...
nature.com
High-throughput measurements of protein domain functions using magnetic separation - Nature Protocols
This Protocol presents a scalable magnetic separation-based method for screening large protein domain libraries in mammalian cells, providing a simple and quantitative alternative to fluorescence-acti...
094
Reposted by Tong Wang
Jason Tan @yjtan.bsky.social · 30/06/2026
Does every enhancer work with every promoter? With @jengreitz.bsky.social and Will Greenleaf, we revisit this long-debated question and resolve an outstanding contradiction in the field. A tour 🧵👇 www.biorxiv.org/content/10.6...
biorxiv.org
Intrinsic promoter responsiveness dictates sensitivity to transcriptional activation by enhancers
Enhancers activate specific target promoters, but whether intrinsic enhancer-promoter compatibility contributes to this specificity is debated. Recent studies using different reporter assays have reac...
37039
Reposted by Tong Wang
NEJM.org @nejm.org · 12/11/2025
Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The @fda.gov outlines a path to market entry for products where a randomized trial is not feasible. Learn more: nej.md/4nUQdcl
Sounding Board 
"Nearly 30 years after the sequencing of the human genome, bespoke therapies are close to reality. The FDA will work as a partner and guide in ushering these therapies to market, and our regulatory strategies will evolve to match the pace of scientific advances." 

"FDA’s New Plausible Mechanism Pathway Vinay" by Prasad, M.D., M.P.H., and Martin A. Makary, M.D., M.P.H.
113
Reposted by Tong Wang
60 Minutes @60minutes.bsky.social · 10/11/2025
After leukemia treatments failed, Alyssa Tapley, at age 13, was told she would die. Then, doctors tried an experimental gene-edited therapy. She became the first human to try the treatment made possible by U.S. federal funding. Now 16, she’s cancer-free and planning her future.
411222
Reposted by Tong Wang
Jeremy Berg @jeremymberg.bsky.social · 10/11/2025
Very well done story on 60 Minutes about the harms of grant terminations and freezes at Harvard with Joan Brugge, Don Engbar, David Liu, and a very compelling young cancer patient, now cured with Liu's technology. Transcript and video here www.cbsnews.com/news/researc...
cbsnews.com
Battle between Trump and universities hurting scientific research in need of federal funding
Federal research funding to universities has fueled breakthroughs for years. The White House is pressuring universities to align with the president's political agenda, or risk losing their funding.
315060
Reposted by Tong Wang
Elisabeth Bik @elisabethbik.bsky.social · 07/11/2025
The Editor Got a Letter From ‘Dr. B.S.’ So Did a Lot of Other Editors. The rise of artificial intelligence has produced serial writers to science and medical journals, most likely using chatbots to boost the number of citations they’ve published #GiftLink www.nytimes.com/2025/11/04/s...
nytimes.com
The Editor Got a Letter From ‘Dr. B.S.’ So Did a Lot of Other Editors.
2409
Reposted by Tong Wang
Selin Jessa @selinjessa.com · 07/11/2025
We then used sequence-to-activity deep learning models, to predict effects of non-coding edits on TF binding and chromatin accessibility. We first show that a ChromBPNet model can predict the same GATA site disruption mechanism exploited by the FDA-approved Casgevy medicine, specifically in T cells:
Erythroblast ChromBPNet model predicts impact of known therapeutic CRISPR target (exagamglogene autotemcel, Casgevy) on accessibility a) Schematic of Casgevy mechanism. BCL11A represses fetal hemoglobin in adulthood. Disruption of a BCL11A enhancer reactivates fetal hemoglobin. b) Observed ATAC and predicted accessibility from ChromBPNet BCL11A intron, for T-cells (this study) and erythroblasts 48. c) Predicted accessibility for chr2 60495264: T>C edit and reference sequence in erythroblasts, along with DeepLIFT contribution scores. d) Predicted accessibility of chr2 60495267: T>C edit and reference sequence in erythroblasts. The ABE8e edit window is derived from the highest efficiency gRNA sg1620
101
Reposted by Tong Wang
Selin Jessa @selinjessa.com · 07/11/2025
A highlight of my summer was this collab w/ @twangmdphd.bsky.social ! CRISPR base editors are driving several clinical trials, but it's hard to quantify off-target edits and their effects. Tong developed a sequencing assay to identify off-targets *in primary cells* 🧬🖥️🧪 #genomics #chromatin #CRISPR
142
Reposted by Tong Wang
AI x Bio Discovery @aixbiobot.bsky.social · 26/09/2025
Sensitive, direct detection of non-coding off-target base editor unwinding and editing in primary cells [new] Direct seq. quantifies off-target base editor & DNA unwinding.
Sensitive, direct detection of non-coding off-target base editor unwinding and editing in primary cellsFigure 1Figure 2Figure 3
001
Reposted by Tong Wang
bioRxivpreprint @biorxivpreprint.bsky.social · 26/09/2025
Sensitive, direct detection of non-coding off-target base editor unwinding and editing in primary cells www.biorxiv.org/content/10.1101/202…
001
Tong Wang @twangmdphd.bsky.social · 29/09/2025
1/ Happy to share our preprint from the Greenleaf Lab: beCasKAS, our method to directly detect CRISPR base editor off-targets in primary cells. We additionally show how non-coding edits can be triaged for epigenetic dysregulation using deep learning. www.biorxiv.org/content/10.1...
1134
Reposted by Tong Wang
Selin Jessa @selinjessa.com · 03/05/2025
Delighted to share our latest work deciphering the landscape of chromatin accessibility and modeling the DNA sequence syntax rules underlying gene regulation during human fetal development! www.biorxiv.org/content/10.1... Read on for more: 🧵 1/16 #GeneReg 🧬🖥️
biorxiv.org
Dissecting regulatory syntax in human development with scalable multiomics and deep learning
Transcription factors (TFs) establish cell identity during development by binding regulatory DNA in a sequence-specific manner, often promoting local chromatin accessibility, and regulating gene expre...
212860
Reposted by Tong Wang
Laurence Ettwiller @ettwiller.bsky.social · 09/12/2024
www.biorxiv.org/content/10.1... Our study published today on #bioRxiv describe the identification of a deaminase that converts 5mC to T, enabling direct sequencing of the human methylome and genome. This achievement was made possible through a collaborative effort across all departments at #NEB.
511357
Reposted by Tong Wang
Gang Fang @gangfang.bsky.social · 20/11/2024
(1st post @BlueSky) Preprint alert🚨a long thread. Cautions in the use of @nanopore sequencing to map DNA modifications: officially reported “accuracy” ≠ reliable mapping in real applications. We performed a critical assessment of nanopore sequencing (across different versions of models) for the 1/n
611544
Reposted by Tong Wang
zack chiang @zchiang.bsky.social · 14/11/2024
who knew it would be easier to get everyone to switch social media platforms than getting them to use hg38
1525462